Elixion Biotech takes quantum-informed R&D route for next-gen precision medicines

Skyhawk Therapeutics and Merck KGaA strike $2 billion deal to discover novel RNA for neurological disorders

Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise

Revvity launches reagent technology for targeted therapeutics

Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research

Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease

Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD

Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories

The acquisition will strengthen the overall company’s position as leading global CRO services partner

AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore

Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs

BioVaxys executes LoI for major Immunotherapeutics technology acquisition

BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement

Merck to acquire Caraway Therapeutics

Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases

TransCure bioServices partners with Preclina to expands reach into APAC

Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders

Lonza collaborates with Vertex on cell, gene technologies manufacturing

Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)